Search
Chlormezanone
go.drugbank.com/drugs/DB01178ApprovedWithdrawnIt has been suggested for use in the treatment of muscle spasm.
Metipranolol
go.drugbank.com/drugs/DB01214ApprovedWithdrawnA beta-adrenergic antagonist effective for both beta-1 and beta-2 receptors. It is used as an antiarrhythmic, antihypertensive, and antiglaucoma agent.
Propiolactone
go.drugbank.com/drugs/DB09348ApprovedWithdrawnPropiolactone is a disinfectant used for the sterilization of blood plasma, vaccines, tissue grafts, surgical instruments, and enzymes. It has been used against bacteria, fungi, and virus. … [A32144] It is currently FDA approved for its use as an indirect additive used in food contact substances. Propiolactone was first commercially available in the United States in 1958.[A32144]
Fluvastatin
go.drugbank.com/drugs/DB01095ApprovedInvestigationalFluvastatin is an antilipemic agent that competitively inhibits hydroxymethylglutaryl-coenzyme A (HMG-CoA) reductase. HMG-CoA reductase catalyzes the conversion of HMG-CoA to mevalonic acid, the rate-limiting step in cholesterol biosynth...
Categories: Hypolipidemic Agents Indicated for HyperlipidemiaPeginterferon beta-1a
go.drugbank.com/drugs/DB09122ApprovedInvestigationalIt was originally approved by the FDA in 2014 for subcutaneous use, and was approved for intramuscular use in January 2021. … [A176474,L5792] Peginterferon beta-1a is an interferon therapy used for the management of relapsing forms of MS.
Haemagglutinin-strain B
go.drugbank.com/drugs/DB15482ApprovedInvestigationalMixtures: Influvac Suspension for InjectionLormetazepam
go.drugbank.com/drugs/DB13872ApprovedLormatazepam is an orally available benzodiazepine used in the UK for the treatment of short-term insomnia [L927].
Brepocitinib
go.drugbank.com/drugs/DB15003ApprovedInvestigational[L64097] The FDA approved brepocitinib on August 27, 2026 for the treatment of dermatomyositis in adult patients, making it the first targeted oral therapy approved for the condition.[L64115]
Nerandomilast
go.drugbank.com/drugs/DB18237ApprovedInvestigationalFDA approved nerandomilast tablets for the treatment of progressive pulmonary fibrosis (PPF) in adults. … [L54126] On October 7, 2025, nerandomilast was approved as the first new treatment for idiopathic pulmonary fibrosis in more than a decade.
EVT 302
go.drugbank.com/drugs/DB06057InvestigationalIt is in the development for smoking cessation, and potential for disease modification in Alzheimer's disease.